TARGETED siRNA DELIVERY AS AN ANTI-HIV MICROBICIDE
TARGETED siRNA DELIVERY AS AN ANTI-HIV MICROBICIDE
批准号:
8708746
负责人:
Derek Michael Dykxhoorn
金额:
$40.54万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-05-15 至 2016-06-30
关键词:
Anti-Retroviral AgentsAntibodiesBiological ModelsCD4 Positive T LymphocytesCell LineCell physiologyCellsClinicalComplementCytoplasmDendritic CellsDependencyDevelopmentDiseaseDrug TargetingEnsureEventExploratory/Developmental Grants Phase IIGene SilencingGene Silencing PathwayGene TargetingGenesGenetic MaterialsGenomeHIVHIV Long Terminal RepeatHIV vaccineHIV-1HeterogeneityHeterosexualsImmune systemImmunityIndividualInfectionInfection preventionIntegration Host FactorsIntegrinsLeftLife Cycle StagesLipidsLiposomesLymphocyteMammalian CellMediatingMethodsMucous MembraneMutateOpportunistic InfectionsPhasePreventionProcessProductionProteinsRNA InterferenceReagentResearchSafetySatellite VirusesSexual TransmissionSmall Interfering RNASmall RNAStagingStructureSubfamily lentivirinaeSurfaceSystemT-LymphocyteTestingTherapeuticTopical applicationVaccinesVaginaViralViral GenomeVirionVirusVirus DiseasesVirus IntegrationVirus Replicationbasecell typeclinical applicationefficacy testinggene functiongene therapyin vitro testingin vivointerestmacrophagemicrobicidemouse modelnanoparticlenovelnovel therapeuticspathogenpre-clinicalpreventresearch studyscreeningtherapeutic genetherapeutic targettissue culturetooltransmission processuptakeviral RNA
中文摘要
靶向siRNA递送作为抗HIV杀微生物剂PI:Derek M. Dykxhoorn
项目摘要:
人类免疫缺陷病毒(HIV)是一种高致死性慢病毒,在一个漫长的过程中,
宿主的适应性免疫系统使它们容易受到许多机会性感染。不像大多数
对于基因组独立于宿主细胞基因组复制的病毒,HIV-1基因组整合到
并与宿主遗传物质一起复制。因此,即使治疗方法可以抑制新的病毒,
在生产过程中,病毒基因组保持完整和有能力。因此,可以防止摄取的策略
病毒的整合将具有巨大的临床价值。绝大多数艾滋病毒感染发生在
病毒通过粘膜表面如阴道粘膜传播的结果。提供
特异性沉默HIV生命周期早期事件所需的宿主因子的siRNA,
阴道粘膜可以被证明是一种有效的手段,保护个人免受艾滋病毒感染,并作为
一种潜在的杀菌剂siRNA作为基因治疗药物的临床应用所面临的主要挑战之一是,
治疗的一个重要方面是将siRNA递送至适当靶细胞类型的细胞质的能力。我们最近
开发了一种新的脂质纳米颗粒,其包被有识别整合素分子LFA-1的抗体
其在淋巴细胞上广泛表达。这些免疫纳米颗粒将用于将siRNA递送至
HIV的人源化小鼠模型的阴道粘膜中存在的淋巴细胞。鉴于高水平的
序列异质性、HIV-1突变的倾向以及抗HIV siRNA不能靶向HIV-1,
进入病毒RNA基因组并阻止整合,需要替代治疗靶点来阻止病毒RNA基因组的整合。
艾滋病毒的传播。宿主因素是HIV生命周期中早期事件所必需的,
可以证明是一种有效的治疗方法。使用高通量RNA
基于干扰的筛选平台,我们已经确定了大量潜在的治疗靶点,
可以抑制艾滋病毒的整合。然而,这些因素需要广泛的分析,
以确保其安全性和有效性。我们将结合LFA-1介导的细胞类型特异性
载体引入靶向治疗相关宿主因子的siRNA作为抑制病毒感染的潜在手段
HIV的人源化小鼠模型中的感染。这些实验将提供临床前基础
这是开发有效的基于RNAi的抗HIV杀微生物剂所必需的。
英文摘要
Targeted siRNA delivery as an anti-HIV microbicide PI: Derek M. Dykxhoorn
Project Summary:
Human immunodeficiency virus (HIV) is a highly lethal lentivirus which over a protracted course destroys the
host's adaptive immune system leaving them vulnerable to numerous opportunistic infections. Unlike most
viruses whose genome replicates independently of the host cell's genome, the HIV-1 genome integrates into
and is replicated with the host genetic material. Therefore, even if therapeutic approaches can inhibit new virus
production, the viral genome remains intact and competent. Therefore, strategies that can prevent the uptake
and integration of the virus would be of tremendous clinical value. The vast majority of HIV infections occur as
a consequence of viral transmission through mucosal surfaces, such as the vaginal mucosa. The delivery of
siRNAs that specifically silence host factors required for early events in the HIV life cycle to lymphocytes in the
vaginal mucosa could prove to be an effective means of protecting individuals from HIV infection and serve as
a potential microbicide. One of the main challenges facing the clinical application of siRNAs as a genetic
therapy is the ability to delivery siRNAs to the cytoplasm of the appropriate target cell types. We have recently
developed a novel lipid nanoparticle that is coated with an antibody recognizing the integrin molecule LFA-1
which is broadly expressed on lymphocytes. These immuno-nanoparticles will be used to deliver siRNAs to
lymphocytes present in the vaginal mucosa of humanized mouse models of HIV. Given the high level of
sequence heterogeneity, the propensity of HIV-1 to mutate and the inability of anti-HIV siRNAs to target the
incoming viral RNA genome and prevent integration, alternative therapeutic targets are required to prevent the
transmission of HIV. Host factors that are necessary for early events in the HIV lifecycle but are dispensable
for cellular functioning could prove to be an effective therapeutic alternative. Using a high-throughput RNA
interference-based screening platform, we have identified a large number of potential therapeutic targets that
could serve to inhibit HIV integration when silenced. However, these factors require extensive analysis and
characterization to ensure their safety and efficacy. We will be combining the LFA-1-mediated cell-type specific
vehicle to introduce siRNAs targeting therapeutically relevant host factors as a potential means to inhibit viral
infection in humanized mouse models of HIV. These experiments will provide the preclinical groundwork
necessary for the development of an effective RNAi-based anti-HIV microbicide.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Polyunsaturated fatty acids as anti-arrhythmic agents.
-
批准号:10483411
-
项目类别:
-
资助金额:$11.29万
-
财政年份:2022
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Polyunsaturated fatty acids as anti-arrhythmic agents.
-
批准号:10874097
-
项目类别:
-
资助金额:$5.8万
-
财政年份:2022
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Functional genomic studies in diverse populations to characterize risk loci for Alzheimer Disease
-
批准号:10442439
-
项目类别:
-
资助金额:$138.17万
-
财政年份:2021
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Functional genomic studies in diverse populations to characterize risk loci for Alzheimer Disease
-
批准号:10217547
-
项目类别:
-
资助金额:$141.01万
-
财政年份:2021
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Functional genomic studies in diverse populations to characterize risk loci for Alzheimer Disease
-
批准号:10681312
-
项目类别:
-
资助金额:$138.09万
-
财政年份:2021
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Polyunsaturated fatty acids as anti-arrhythmic agents.
-
批准号:10369727
-
项目类别:
-
资助金额:$60.73万
-
财政年份:2016
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Polyunsaturated fatty acids as anti-arrhythmic agents.
-
批准号:10755511
-
项目类别:
-
资助金额:$11.79万
-
财政年份:2016
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Polyunsaturated fatty acids as anti-arrhythmic agents.
-
批准号:10210907
-
项目类别:
-
资助金额:$64.4万
-
财政年份:2016
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Polyunsaturated fatty acids as anti-arrhythmic agents.
-
批准号:10836101
-
项目类别:
-
资助金额:$6.25万
-
财政年份:2016
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
TARGETED siRNA DELIVERY AS AN ANTI-HIV MICROBICIDE
-
批准号:8071962
-
项目类别:
-
资助金额:$17.63万
-
财政年份:2010
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
TARGETED siRNA DELIVERY AS AN ANTI-HIV MICROBICIDE
-
批准号:8880097
-
项目类别:
-
资助金额:$40.63万
-
财政年份:2010
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
TARGETED siRNA DELIVERY AS AN ANTI-HIV MICROBICIDE
-
批准号:8650542
-
项目类别:
-
资助金额:$38.52万
-
财政年份:2010
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
TARGETED siRNA DELIVERY AS AN ANTI-HIV MICROBICIDE
-
批准号:7893489
-
项目类别:
-
资助金额:$18.95万
-
财政年份:2010
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Disease Modeling Core
-
批准号:8740573
-
项目类别:
-
资助金额:$27.92万
-
财政年份:--
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Disease Modeling Core
-
批准号:8268810
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Disease Modeling Core
-
批准号:8932825
-
项目类别:
-
资助金额:$26.83万
-
财政年份:--
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Disease Modeling Core
-
批准号:8539103
-
项目类别:
-
资助金额:$13.31万
-
财政年份:--
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
Disease Modeling Core
-
批准号:8379528
-
项目类别:
-
资助金额:$8.43万
-
财政年份:--
-
负责人:Derek Michael Dykxhoorn
-
依托单位:
海外基金